Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid ...

Novartis faces short-term challenges with patent expirations but shows long-term growth potential. Click here to read why I ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

The U.S. Court of Appeals for the Federal Circuit (CAFC) today issued a precedential decision reversing a district court’s ...

The Federal Circuit reversed a Delaware district court’s 2023 ruling axing a Novartis Pharmaceuticals Corp. patent covering ...

Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

Novartis’ Zolgensma, an IV formulation, was FDA-approved in 2019 for patients under two with SMA. However, the new IT ...

Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025Additional clinical ...

Range Financial Group LLC acquired a new stake in shares of Novartis AG (NYSE:NVS – Free Report) in the fourth quarter, ...

Marea’s Phase IIa study enrolled patients with hypertriglyceridemia—too much fat in the blood. The latest results showed the ...